Format

Send to

Choose Destination
Clin Cancer Res. 2015 Aug 1;21(15):3428-35. doi: 10.1158/1078-0432.CCR-14-3253. Epub 2015 Apr 13.

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.

Author information

1
Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada.
2
Département de bio-pathologie, Institut Paoli-Calmettes, Marseille, France.
3
Lymphoma Academic Research Organisation, Centre Hospitalier Lyon-Sud, Lyon, France.
4
Hematology, University Hospital, Vandoeuvre Les Nancy, France.
5
Pathology, Hôpital Necker, Paris, France.
6
Hematology, Hopital Saint Louis, Paris, France.
7
Medical Biophysics, BC Cancer Agency, Vancouver, British Columbia, Canada.
8
Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada.
9
APHP, Hôpital Saint-Antoine, Paris, France.
10
Lymphoid Malignancies Unit, Hôpital Henri Mondor, Créteil and University Paris Est Créteil, France.
11
Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada. gilles.salles@chu-lyon.fr rgascoyn@bccancer.bc.ca.
12
Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite, France. gilles.salles@chu-lyon.fr rgascoyn@bccancer.bc.ca.

Abstract

PURPOSE:

We aimed to assess the prognostic significance of follicular lymphoma-associated macrophages in the era of rituximab treatment and maintenance.

EXPERIMENTAL DESIGN:

We applied immunohistochemistry for CD68 and CD163 to two large tissue microarrays (TMA). The first TMA included samples from 186 patients from the BC Cancer Agency (BCCA) who had been treated with first-line systemic treatment including rituximab, cyclophosphamide, vincristine, and prednisone. The second contained 395 samples from PRIMA trial patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and randomized to rituximab maintenance or observation. Macrophage infiltration was assessed using Aperio image analysis. Each of the two cohorts was randomly split into training/validation sets.

RESULTS:

An increased CD163-positive pixel count was predictive of adverse outcome in the BCCA dataset [5-year progression-free survival (PFS) 38% vs. 72%, respectively, P = 0.004 in the training cohort and 5-year PFS 29% vs. 61%, respectively, P = 0.004 in the validation cohort]. In the PRIMA trial, an increased CD163 pixel count was associated with favorable outcome (5-year PFS 60% vs. 44%, respectively, P = 0.011 in the training cohort and 5-year PFS 55% vs. 37%, respectively, P = 0.030 in the validation cohort).

CONCLUSIONS:

CD163-positive macrophages predict outcome in follicular lymphoma, but their prognostic impact is highly dependent on treatment received.

PMID:
25869385
DOI:
10.1158/1078-0432.CCR-14-3253
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center